Copyright Notice

CPT codes, descriptions and other data only are copyright 2023 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply. Fee schedules, relative value units, conversion factors and/or related components aren't assigned by the AMA, aren't part of CPT, and the AMA isn't recommending their use. The AMA doesn't directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

Coverage & Billing Information for the 2023 Quarterly Code Update

lowa Medicaid has reviewed the Q3 2023 Billing Code Update to determine coverage and billing guidelines. The lowa Medicaid coverage and billing information provided in this bulletin is effective July 1, 2023. This bulletin serves as a notice of the following information:

Table I

New Current Procedural Terminology (CPT[®]) and Healthcare Common Procedure Coding System (HCPCS) codes included in the Q1 2023 code update. Coverage and billing information for these codes applies to dates of service on or after July 1, 2023.

Table 2

New Current Dental Terminology (CDT©) codes included in the Q1 2023 code update. Coverage and billing information for these codes applies to dates of service on or after N/A.

Table 3

International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes. Coverage and billing for these codes applies to dates of service on or after N/A.

Table 4

International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-I0-PCS) codes. Coverage and billing for these codes applies to dates of service on or after N/A.

Table 5

 Modifiers included in the code update. Coverage and billing information for these codes applies to dates of service on or after July 1, 2023.

Table 6

 CPT[®], CDT[®], & HCPCS codes that would be considered Outpatient Hospital on or after July 1, 2023.

Table 7

■ Non-Covered Codes - CPT®, CDT®, HCPCS, ICD-10-CM & ICD-10-PCS codes that have been thoroughly reviewed and Iowa Medicaid has decided not to cover effective July 1, 2023.

Table 8

 Deleted Codes - CPT©, CDT©, HCPCS, ICD-10-CM & ICD-10-PCS codes that have been discontinued effective June 30, 2023.



Managed Care Organization (MCOs) establish and publish reimbursement, PA, and billing information within the managed care delivery system. Questions about managed care PA should be directed to the MCP with which the member is enrolled.

Iowa Medicaid Provider Services:

Phone: I-800-338-7909

Email: imeproviderservices@dhs.state.ia.us

Wellpoint Iowa, Inc.:

• Phone: I-833-731-2143

• Email: ProviderSolutionsIA@wellpoint.com

• Website: https://www.provider.wellpoint.com/iowa-provider/home

Iowa Total Care:

Phone: I-833-404-1061

Email: providerrelations@iowatotalcare.com

• Website: https://www.iowatotalcare.com

Molina Healthcare of Iowa:

• Phone: I-844-236-1464

• Email: iaproviderrelations@molinahealthcare.com

• Website: https://www.molinahealthcare.com/providers/ia/medicaid/home.aspx

• Provider portal: https://www.availity.com/molinahealthcare

The **Q3 2023** code update may include modifications to descriptions for some existing HCPCS/CPT codes. These modifications are available for reference or download from the CMS website at www.cms.gov.

The Q3 code update also includes a list of deleted codes. These codes are available for reference or download from the CMS website at cms.gov. If there is a replacement code, lowa Medicaid has added the replacement code for which there were deleted codes effective as of July 1, 2023.

Special Billing Information in Table I shows if the code requires a Prior Authorization or if it suspends for claim review. If the column is blank, there is no special billing information.

Iowa Medicaid will update the fee schedule as rates become available.

STATE OF IOWA DEPARTMENT OF Health and Human SERVICES

Back to top

Code	Description	Effective Date	Special Billing Information
0792T	Application of 38% silver diamine fluoride by a physician or other qualified health care professional	7/1/2023	
C9150	Xenon xe-129 hyperpolarized gas, diagnostic, per study dose	7/1/2023	
C9151	Injection, pegcetacoplan, I mg	7/1/2023	PA Required
C9786	Echocardiography image post processing for computer aided detection of heart failure with preserved ejection fraction, including interpretation and report	7/1/2023	
J0137	Injection, acetaminophen (hikma) not therapeutically equivalent to j0131, 10 mg	7/1/2023	
J0206	Injection, allopurinol sodium, 1 mg	7/1/2023	
J0216	Injection, alfentanil hydrochloride, 500 micrograms	7/1/2023	
J0457	Injection, aztreonam, 100 mg	7/1/2023	
J0665	Injection, bupivacaine, not otherwise specified, 0.5 mg	7/1/2023	
J0736	Injection, clindamycin phosphate, 300 mg	7/1/2023	
J0737	Injection, clindamycin phosphate (baxter), not therapeutically equivalent to J0736, 300 mg	7/1/2023	
J1440	Fecal microbiota, live - jslm, 1 mL	7/1/2023	
J1576	Injection, immune globulin (panzyga), intravenous, non-lyophilized (e.g., liquid), 500 mg	7/1/2023	PA Required
J1805	Injection, esmolol hydrochloride, 10 mg	7/1/2023	
J1806	Injection, esmolol hydrochloride (wg critical care) not therapeutically equivalent to j1805, 10 mg	7/1/2023	
J1811	Insulin (fiasp) for administration through dme (i.e., insulin pump) per 50 units	7/1/2023	
J1812	Insulin (fiasp), per 5 units	7/1/2023	
J1813	Insulin (lyumjev) for administration through dme (i.e., insulin pump) per 50 units	7/1/2023	PA Required
J1814	Insulin (lyumjev), per 5 units	7/1/2023	
J1836	Injection, metronidazole, 10 mg	7/1/2023	
J1920	Injection, labetalol hydrochloride, 5 mg	7/1/2023	
J1921	Injection, labetalol hydrochloride (hikma) not therapeutically equivalent to J1920, 5 mg	7/1/2023	
J1941	Injection, furosemide (furoscix), 20 mg	7/1/2023	
J1961	Injection, lenacapavir, I mg	7/1/2023	
J2249	Injection, remimazolam, I mg	7/1/2023	
J2305	Injection, nitroglycerin, 5 mg	7/1/2023	
J2329	Injection, ublituximab-xiiy, Img	7/1/2023	PA Required
J2371	Injection, phenylephrine hydrochloride, 20 micrograms	7/1/2023	·
J2372	Injection, phenylephrine hydrochloride (biorphen), 20 micrograms	7/1/2023	

Health AND Human

SERVICES

J2427	Injection, paliperidone palmitate extended release (invega hafyera, or invega trinza), I mg	7/1/2023	
J2561	Injection, phenobarbital sodium (sezaby), 1 mg	7/1/2023	
J2598	Injection, vasopressin, I unit	7/1/2023	
J2599	Injection, vasopressin (american regent) not therapeutically equivalent to j2598, 1 unit	7/1/2023	
J2806	Injection, sincalide (maia) not therapeutically equivalent to J2805, 5 micrograms	7/1/2023	
J7213	Injection, coagulation factor ix (recombinant), ixinity, 1 i.u.	7/1/2023	
J9029	Injection, nadofaragene firadenovec-vncg, per therapeutic dose	7/1/2023	PA Required
J9056	Injection, bendamustine hydrochloride (vivimusta), I mg	7/1/2023	
J9058	Injection, bendamustine hydrochloride (apotex), I mg	7/1/2023	
J9059	Injection, bendamustine hydrochloride (baxter), I mg	7/1/2023	
J9063	Injection, mirvetuximab soravtansine-gynx, 1 mg	7/1/2023	PA Required
J9259	Injection, paclitaxel protein-bound particles (american regent) not therapeutically equivalent to J9264, I	7/1/2023	
	mg		
J9322	Injection, pemetrexed (bluepoint) not therapeutically equivalent to J9305, 10 mg	7/1/2023	
J9323	Injection, pemetrexed ditromethamine, 10 mg	7/1/2023	
J9347	Injection, tremelimumab-actl, I mg	7/1/2023	PA Required
J9350	Injection, mosunetuzumab-axgb, 1 mg	7/1/2023	PA Required
J9380	Injection, teclistamab-cqyv, 0.5 mg	7/1/2023	PA Required
J9381	Injection, teplizumab-mzwv, 5 mcg	7/1/2023	PA Required
Q5131	Injection, adalimumab-aacf (idacio), biosimilar, 20 mg	7/1/2023	
			-

^{*}Covid Related Code

Table 2 - CDT©

Code	Description	Effective Date	
N/A	N/A	N/A	
		Back to top	

Table 3 – ICD-10-CM Codes

Code	Description	Effective Date	
N/A	N/A	N/A	
		Back to top	

Table 4 - ICD-10-PCS Codes

Code	Description	Effective Date
N/A	N/A	N/A

Back to top

Back to top

STATE OF IOWA DEPARTMENT OF Health and Human Services

Table 5 – Modifiers

Modifier	Description	Effective Date
N/A	N/A	N/A

Back to top

Table 6 – Outpatient Hospital

Code	Description	Effective Date
C9150	Xenon xe-129 hyperpolarized gas, diagnostic, per study dose	7/1/2023
C9151	Injection, pegcetacoplan, 1 mg	7/1/2023
C9786	Echocardiography image post processing for computer aided detection of heart failure with preserved ejection	7/1/2023
	fraction, including interpretation and report	
J0137	Injection, acetaminophen (hikma) not therapeutically equivalent to j0131, 10 mg	7/1/2023
J0206	Injection, allopurinol sodium, 1 mg	7/1/2023
J0216	Injection, alfentanil hydrochloride, 500 micrograms	7/1/2023
J0457	Injection, aztreonam, 100 mg	7/1/2023
J0665	Injection, bupivacaine, not otherwise specified, 0.5 mg	7/1/2023
J0736	Injection, clindamycin phosphate, 300 mg	7/1/2023
J0737	Injection, clindamycin phosphate (baxter), not therapeutically equivalent to J0736, 300 mg	7/1/2023
J1440	Fecal microbiota, live - jslm, I mL	7/1/2023
J1576	Injection, immune globulin (panzyga), intravenous, non-lyophilized (e.g., liquid), 500 mg	7/1/2023
J1805	Injection, esmolol hydrochloride, 10 mg	7/1/2023
J1806	Injection, esmolol hydrochloride (wg critical care) not therapeutically equivalent to j1805, 10 mg	7/1/2023
J1811	Insulin (fiasp) for administration through dme (i.e., insulin pump) per 50 units	7/1/2023
J1812	Insulin (fiasp), per 5 units	7/1/2023
J1813	Insulin (lyumjev) for administration through dme (i.e., insulin pump) per 50 units	7/1/2023
J1814	Insulin (lyumjev), per 5 units	7/1/2023
J1836	Injection, metronidazole, 10 mg	7/1/2023
J1920	Injection, labetalol hydrochloride, 5 mg	7/1/2023
J1921	Injection, labetalol hydrochloride (hikma) not therapeutically equivalent to J1920, 5 mg	7/1/2023
J1941	Injection, furosemide (furoscix), 20 mg	7/1/2023
J1961	Injection, lenacapavir, 1 mg	7/1/2023
J2249	Injection, remimazolam, 1 mg	7/1/2023
J2305	Injection, nitroglycerin, 5 mg	7/1/2023
J2329	Injection, ublituximab-xiiy, 1mg	7/1/2023
J2371	Injection, phenylephrine hydrochloride, 20 micrograms	7/1/2023

Health AND Human

SERVICES

J2372	Injection, phenylephrine hydrochloride (biorphen), 20 micrograms	7/1/2023
J2427	Injection, paliperidone palmitate extended release (invega hafyera, or invega trinza), I mg	7/1/2023
J2561	Injection, phenobarbital sodium (sezaby), 1 mg	7/1/2023
J2598	Injection, vasopressin, I unit	7/1/2023
J2599	Injection, vasopressin (american regent) not therapeutically equivalent to j2598, 1 unit	7/1/2023
J2806	Injection, sincalide (maia) not therapeutically equivalent to J2805, 5 micrograms	7/1/2023
J7213	Injection, coagulation factor ix (recombinant), ixinity, 1 i.u.	7/1/2023
J9029	Injection, nadofaragene firadenovec-vncg, per therapeutic dose	7/1/2023
J9056	Injection, bendamustine hydrochloride (vivimusta), 1 mg	7/1/2023
J9058	Injection, bendamustine hydrochloride (apotex), 1 mg	7/1/2023
J9059	Injection, bendamustine hydrochloride (baxter), I mg	7/1/2023
J9063	Injection, mirvetuximab soravtansine-gynx, 1 mg	7/1/2023
J9259	Injection, paclitaxel protein-bound particles (american regent) not therapeutically equivalent to J9264, 1 mg	7/1/2023
J9322	Injection, pemetrexed (bluepoint) not therapeutically equivalent to J9305, 10 mg	7/1/2023
J9323	Injection, pemetrexed ditromethamine, 10 mg	7/1/2023
J9347	Injection, tremelimumab-actl, I mg	7/1/2023
J9350	Injection, mosunetuzumab-axgb, 1 mg	7/1/2023
J9380	Injection, teclistamab-cqyv, 0.5 mg	7/1/2023
J9381	Injection, teplizumab-mzwv, 5 mcg	7/1/2023
Q5131	Injection, adalimumab-aacf (idacio), biosimilar, 20 mg	7/1/2023

Back to top

Table 7 – Non-covered codes

Code	Desc
0387U	Tissue evaluation for proteins to report risk of skin cancer progression
0388U	Next-generation sequencing in plasma of 37 cancer related genes, with report for alteration detection in non-small cell lung cancer
0389U	Reverse transcription polymerase chain reaction (RTqPCR) testing of blood for proteins, reported as a risk score for Kawasaki disease
0390U	Immunoassay of serum for proteins, reported as a risk score for preeclampsia
0391U	DNA and RNA next-generation sequencing of tissue for 437 genes with algorithm quantifying immunotherapy response score
0392U	Evaluation of gene-drug interactions for 16 genes reported as impact of gene-drug interaction for each drug for depression, anxiety, attention
	deficit disorder
0393U	Detection of protein by seed amplification assay for neurological disorders
0394U	Testing of plasma or serum for 16 perfluoroalkyl substances (PFAS) compounds
0395U	Multi-omics testing of plasma reported as risk of malignancy for lung nodules in early-stage lung cancer

Health AND Human

SERVICES

0396U	Microarray testing of embryonic tissue for 300000 DNA single-nucleotide polymorphisms (SNPs), reported as a probability for single-gene
	germline conditions in pre-implantation genetic testing
0397U	Cell-free DNA testing in plasma evaluating of at least 109 genes in non-small cell lung cancer
0398U	DNA methylation analysis using polymerase chain reaction testing of tissue for genes specific to Barrett esophagus, reported as a risk score
	for progression to high grade dysplasia or cancer
0399U	Enzyme-linked assay detection in serum of IgGbinding antibody and blocking autoantibodies, using a functional blocking assay for IgG or IgM reported as positive or not detected in cerebral folate deficiency
0400U	Next-generation sequencing of DNA for 145 genes reported as carrier positive or negative in expanded carrier screening
0401U	Targeted variant genotyping using blood, saliva, or buccal swab of 9 genes for coronary heart disease reported as a risk score for a coronary event
0791T	Semi-immersive virtual reality-facilitated, motor cognitive training for walking, each 15 minutes
0793T	Percutaneous transcatheter thermal ablation of pulmonary artery nerves, including right heart catheterization, pulmonary artery angiography, and all imaging guidance
0794T	Pt-specific, assistive, rules-based algorithm for ranking cancer drug tx options based on the pt's tumor-specific cancer marker information obtained from previous lab testing which have been previously I & R separately
0795T	Transcatheter insertion of permanent dual-chamber leadless pacemaker using fluoroscopy and device interrogation of right atrial and right ventricular pacemaker components
0796T	Transcatheter insertion of permanent dual-chamber pacemaker using fluoroscopy and device interrogation of right atrial pacemaker component
0797T	Transcatheter insertion of a permanent dual chamber leadless pacemaker using fluoroscopy and device interrogation of right ventricular pacemaker component
0798T	Transcatheter removal of the right atrial and right ventricular components of a permanent dual-chamber leadless pacemaker using fluoroscopy
0799T	Transcatheter removal of the right atrial component of a permanent dual-chamber leadless pacemaker using fluoroscopy
T0080	Transcatheter removal of the right ventricular component of a permanent dual-chamber leadless pacemaker using fluoroscopy
080IT	Transcatheter removal and replacement of permanent dual-chamber leadless pacemaker using fluoroscopy and device interrogation of right atrial and right ventricular components
0802T	Transcatheter removal and replacement of permanent dual-chamber leadless pacemaker using fluoroscopy and device interrogation of right atrial component
0803T	Transcatheter removal and replacement of permanent dual-chamber leadless pacemaker using fluoroscopy and device interrogation of right ventricular component
0804T	In-person programming device eval of dualchamber leadless pacemaker w/ adjustment of the device to test function & to select optimal permanent values, w/ analysis, review&report by a physician or other qualified professional
0805T	Transcatheter superior and inferior vena cava prosthetic valve implantation (ie, caval valve implantation [CAVI]); percutaneous femoral vein approach
T9080	Transcatheter superior and inferior vena cava prosthetic valve implantation (ie, caval valve implantation [CAVI]); open femoral vein approach

Health AND Human

SERVICES

0807T	Analysis of lung tissue ventilation using softwarebased processing of cinefluorography images and previously acquired CT images, including data
	preparation and transmission, eval of lung tissue ventilation data, review, I & R
T8080	Analysis of lung tissue ventilation using softwarebased processing of cinefluorography images&CT images taken for the purpose of lung tissue
	ventilation analysis, including data preparation and transmission
0809T	Sacroiliac joint fusion, with image guidance, placement of transfixing device(s) and intra-articular implant(s), including tissue graft or synthetic
	device(s), through the skin
T0180	Subretinal injection of a drug, including vitrectomy and retinotomy
C9784	Gastric restrictive procedure, endoscopic sleeve gastroplasty, with esophagogastroduodenoscopy and intraluminal tube insertion, if
	performed, including all system and tissue anchoring components
C9785	Endoscopic outlet reduction, gastric pouch application, with endoscopy and intraluminal tube insertion, if performed, including all system and
	tissue anchoring components
C9787	Gastric electrophysiology mapping with simultaneous patient symptom profiling
Q4272	Esano a, per square centimeter
Q4273	Esano aaa, per square centimeter
Q4274	Esano ac, per square centimeter
Q4275	Esano aca, per square centimeter
Q4276	Orion, per square centimeter
Q4277	Woundplus membrane or e-graft, per square centimeter
Q4278	Epieffect, per square centimeter
Q4280	Xcell amnio matrix, per square centimeter
Q4281	Barrera sl or barrera dl, per square centimeter
Q4282	Cygnus dual, per square centimeter
Q4283	Biovance tri-layer or biovance 3I, per square centimeter
Q4284	Dermabind sl, per square centimeter
	D. L. C.

Back to top

Table 8 – Deleted Codes

Code	Desc		Replacement
		Date	Code (if applicable)
J2370	Injection, phenylephrine HCl, up to 1 ml	6/30/2023	N/A
S0020	Injection, bupivicaine HCl, 30 ml	6/30/2023	N/A
S0030	Injection, metronidazole, 500 mg	6/30/2023	N/A
S0073	Injection, aztreonam, 500 mg	6/30/2023	N/A
S0077	Injection, clindamycin phosphate, 300 mg	6/30/2023	N/A

STATE OF IOWA DEPARTMENT OF Health and Human

SERVICES

U0003	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2	6/30/2023	N/A
	(SARS-CoV-2) (coronavirus disease [COVID-19]), amplified probe technique, making use of high throughput		
	technologies as described by CMS-2020-01-R		
U0004	2019-nCoV coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes	6/30/2023	N/A
	(includes all targets), non-CDC, making use of high throughput technologies as described by CMS-2020-01-R		
U0005	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2	6/30/2023	N/A
	(SARS-CoV-2) (coronavirus disease [COVID-19]), amplified probe technique, CDC or non-CDC, making use		
	of high throughput technologies, completed within 2 calendar days from date of specimen collection (list		
	separately in addition to either HCPCS code U0003 or U0004) as described by CMS-2020-01-R2		

Back to top